Palmitic acid in the sn-2 position decreases glucose-dependent insulinotropic polypeptide secretion in healthy adults

What Was Tested

This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide).

The researchers tested this hypothesis by comparing postprandial responses to fats with varying proportions of palmitic acid in the sn-2 position.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Using a crossover-designed randomized controlled trial in healthy men (n=25) and women (n=25), the researchers compared four meals on postprandial changes in glucose (primary outcome), insulin, C-peptide, glucose, glucose-dependent insulinotropic polypeptide (GIP) and polypeptide YY (PYY) concentrations.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on GIP (Gastric Inhibitory Polypeptide), so expectations could not easily colour the readings.

In the crossover set-up each of the participants took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Blood Glucose, C-Peptide, Dietary Fats, Gastric Inhibitory Polypeptide, Healthy Volunteers, Insulin and Meals.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of GIP (Gastric Inhibitory Polypeptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (European journal of clinical nutrition), a journal based in England.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.